COMPOSITION FOR DIAGNOSIS OR TREATMENT OF A CONDITION ASSOCIATED WITH INCREASED ACTIVITY OF EIF4E COMPRISING AN EIF4E INHIBITOR
20220348916 · 2022-11-03
Inventors
- Jeong Ho Lee (Daejeon, KR)
- Jang Keun KIM (Daejeon, KR)
- Byung Tae KIM (Daejeon, KR)
- Sun-Gyun KIM (Daejeon, KR)
Cpc classification
A61K31/155
HUMAN NECESSITIES
C40B40/08
CHEMISTRY; METALLURGY
A61K31/7056
HUMAN NECESSITIES
A01K2267/0356
HUMAN NECESSITIES
C12Q1/6883
CHEMISTRY; METALLURGY
A61K31/7048
HUMAN NECESSITIES
A01K67/0275
HUMAN NECESSITIES
A61K31/7088
HUMAN NECESSITIES
C12N15/113
CHEMISTRY; METALLURGY
C12N15/63
CHEMISTRY; METALLURGY
G01N2800/52
PHYSICS
C12N2310/3231
CHEMISTRY; METALLURGY
C12Q2600/106
CHEMISTRY; METALLURGY
C12N15/67
CHEMISTRY; METALLURGY
International classification
C12N15/113
CHEMISTRY; METALLURGY
A61K31/155
HUMAN NECESSITIES
C12Q1/6883
CHEMISTRY; METALLURGY
Abstract
The present discloses relates to a composition, a kit or a method using an eIF4E inhibitor for diagnosis or treatment of a condition associated with increased activity of eIF4E.
Claims
1. A method for prevention, alleviation, or treatment of a disease associated with an increased activity of eukaryotic translation initiation factor 4E (eIF4E) in brain neuronal cells or a symptom thereof, comprising administering an eIF4E inhibitor to a subject in need thereof.
2. The method of claim 1, wherein the disease is Malformations of Cortical Developments (FMCD).
3. The method of claim 2, wherein the FMCD is focal cortical dysplasia (FCD), hemimegalencephaly (HME), or Tuberous sclerosis complex (TSC).
4. The method of claim 2, wherein the FMCD is FMCD caused by a brain somatic mutation.
5. (canceled)
6. The method of claim 1, wherein the symptom is at least one selected from the group consisting of epilepsy, anxiety, cognitive impairment, short-term memory impairment, motor impairment, social behavior disorder, repetitive behavior disorder, and depression.
7. (canceled)
8. The method of claim 1, wherein the eIF4E inhibitor inhibits or reduces an activity of eIF4E or inhibits expression of eIF4E, or decreases an expressed level of eIF4E.
9. (canceled)
10. The method of claim 1, wherein the eIF4E inhibitor suppresses increased expression of eIF4E activation-sensitive gene, or decreases an expression of eIF4E activation-sensitive gene, wherein the eIF4E activation-sensitive gene includes at least one motif selected from the group consisting of a U-rich motif, a guanine quartet motif, an A-rich motif and a CERT motif, at a 5′-untranslated region.
11. (canceled)
12. The method of claim 1, wherein the eIF4E inhibitor is a compound, a polynucleotide, a peptide or an antibody.
13. The method of claim 1, wherein the eIF4E inhibitor is a cap-binding antagonist, an eIF4E-eIF4G interaction inhibitor, a material reducing the free eIF4E level by binding to eIF4E, an MNK inhibitor of blocking phosphorylation of eIF4E, or a nucleic acid being capable of binding to eIF4E.
14. The method of claim 10, wherein the eIF4E inhibitor is metformin, Ribavirin, 7-BnGMP, 4Ei-1, 4EGI-1, 4E1RCat, Quabain, Perilly alcohol, 4EBP mimetic peptide, GnRH agonist-4EBP fusion peptide, CGP052088, CGP57380, or siRNA, shRNA or antisense oligonucleotide capable of binding to eIF4E.
15. The method of claim 14, wherein the antisense oligonucleotide is an oligonucleotide which inhibits eIF4E expression and has a length of 14 to 30, 15 to 30, 16 to 30, 17 to 30, 18 to 30 or 19 to 30 nucleotides.
16. (canceled)
17. The method of claim 14, wherein the antisense oligonucleotide decreases the expression level of eIF4E to 90% or less of that of a control having a nucleotide sequence of SEQ ID NO: 201.
18. The method of claim 14, wherein the antisense oligonucleotide comprises at least one chemical modification selected from the group consisting of a chemically-modified inter-nucleoside linkage, a chemically-modified sugar moiety, and a chemically-modified nucleobase.
19. The method of claim 18, wherein at least one nucleotide included in the oligonucleotide is at least one selected from the group consisting of 2′-O-methoxyethyl ribose, cET ribose and a locked nucleic acid.
20. The method of claim 19, wherein one to six of the modified nucleotides are included at each end of the oligonucleotide.
21. The method of claim 14, wherein the oligonucleotide comprises at least one chemically-modified inter-nucleoside linkage.
22. The method of claim 18, wherein the chemically-modified inter-nucleoside linkage is a phosphorothioate bond, the chemically-modified sugar moiety is 2′-O-methoxyethyl ribose, or the chemically-modified nucleobase is 5-methylcytosine.
23. The method of claim 14, wherein the oligonucleotide comprises at least one oligonucleotide selected from the group consisting of SEQ ID NOs: 1 to 95 and SEQ ID NOs: 101 to 200.
24. The method of claim 23, wherein the oligonucleotide comprises SEQ ID NO: 96.
25. (canceled)
26. (canceled)
27. The method of claim 1, wherein the eIF4E inhibitor is administered by subcutaneous injection, intravenous injection, intramuscular injection, intra-arterial injection, intraperitoneal injection, Intracerebral injection, intrathecal injection or intracerebroventricular injection.
28. An antisense oligonucleotide wherein the antisense oligonucleotide inhibits expression or activity of eIF4E and has a length of 14 to 30, 15 to 30, 16 to 30, 17 to 30, 18 to 30 or 19 to 30 nucleotides, and wherein the antisense oligonucleotide comprises at least one chemical modification selected from the group consisting of a chemically-modified inter-nucleoside linkage, a chemically-modified sugar moiety, and a chemically-modified nucleobase.
29-42. (canceled)
43. A method of selecting a subject to be administered an eIF4E inhibitor, predicting susceptibility of an eIF4E inhibitor in a subject, or monitoring the efficacy of an eIF4E inhibitor in a subject, by using at least one biomarker selected from the group consisting of eIF4E, an eIF4E activation-sensitive gene of which expression or activity is regulated by eIF4E, and nucleotide molecules encoding same.
44-46. (canceled)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
DETAILED DESCRIPTION
[0117] A better understanding of the present disclosure may be obtained in light of following examples which are set forth to illustrate, but are not to be construed to limit, the present disclosure.
<EXAMPLE 1> Imaging Analysis of Protein Expression in FMCD Patients' Brain Tissues with Mutations in mTOR
[0118] 1-1: Selection of Subject
[0119] Individuals diagnosed with HME, FCD, or TSC who had undergone epilepsy surgery at the Severance Children's Hospital since 2004 were identified. Enrolled individuals met the study entry criteria for FCDII and underwent extensive presurgical evaluations, including video-EEG monitoring, high-resolution MRI, fluorodeoxyglucose proton emission tomography, and subtraction ictal single-photon emission computed tomography, coregistered to MRI, to localize anatomic lesions. Complete resection was defined as resection of all areas of seizure-onset and irritative zones on intracranial EEG.
[0120] Pathological diagnoses of studied individuals with HME, FCD, or TSC were reconfirmed for the present disclosure according to the recent consensus classification by the International League Against Epilepsy Diagnostic Methods Commission. The study was performed and all human tissues were obtained in accordance with protocols approved by Severance Children's Hospital and the Korea Advanced Institute of Science and Technology (KAIST) Institutional Review Board and Committee on Human Research. Informed consent was obtained from the parents of individuals with HME, FCD, and TSC. Healthy adult, control brain samples were obtained from the University of Maryland Brain and Tissue Bank: brain tissues of individuals without neurological disease were obtained.
[0121] Specifically, clinical information of the patients for the samples used in this test is given in Table 3, below. In this table, the UMB groups stand for healthy adult control brain samples that were obtained from the University of Maryland Brain and Tissue Bank.
TABLE-US-00003 TABLE 3 Age Sei- at Age zure first at fre- sei- sur- quen- Tissue Patient ID Age Sex zure gery cy region Etc UMB1712 20 Y male — — — Frontal Post- mortem tissues UMB4917 22 Y male — — — Frontal Post- mortem tissues UMB5309 14 Y female — — — Temporal Post- mortem tissues UMB5408 6 Y male — — — Temporal Post- mortem tissues FCD56 10 Y female 2 Y 6 Y 3/day Frontal — FCD247 11 Y female 1 Y 9 Y N.A. Temporal — FCD254 12 Y male 4 Y 9 Y 10/day Frontal — FCD348 6 Y male 4 Y 5 Y N.A. Frontal — HME20 5 Y female 2 M 9 M 10/day Frontal — HME255 20 Y female 8 Y 17 Y 3/day Temporal — HME338 17 Y female 5 Y 15 Y N.A. Temporal — TSC2 8 Y female 2 Y 4 Y N.A. Temporal — TSC264 2 Y female 1 Y 1 Y 6/day Frontal — TSC357 20 Y male 1 Y 1 Y N.A. Frontal —
[0122] 1-2: Mutation Test
[0123] For the patients TSC2, FCD254, HME255, TSC264, and TSC357 in Table 4 of Example 1-1, mutation information was confirmed by WES (whole exome sequencing), panel sequencing, and amplicon sequencing. Concrete analysis results are summarized in Table 4, below. From the patients, selection was made of patients diagnosed with tuberous sclerosis (TSC), focal cortical dysplasia (FCD), and hemimegalencephaly (HME). The selected TSC, FCD, and HME patients are indicated by TSC2, FCD254, and HME255, respectively.
TABLE-US-00004 TABLE 4 Mu- Mu- Patient tation tated Nucleotide Protein Frequency ID Sequencing type gene changes change (%) TSC2 Whole Germ- TSC2 c.3355C > T p.Gln1119* 36.75 exome line sequencing FCD254 Targeted Somatic MTOR c.4376C > A p.Ala1459Asp 3.29 hybrid capture sequencing HME255 Targeted Somatic MTOR c.4448G > A p.Cys1483Tyr 9.43 hybrid capture sequencing TSC264 Targeted Germ- TSC2 c.3007delG p.Ala1003fs 10.86 hybrid line capture sequencing TSC357 Targeted Germ- TSC2 c.5153A > C p.His1718Pro 31.99 hybrid line capture sequencing
[0124] 1-3: Expression Levels of Phosphorylated 4E-BP1/2/3 (4E-BPs) and S6 in Patient Samples
[0125] Using immunofluorescence staining, the FMCD epilepsy patients (TSC2, FCD254, and HME255) in Example 1-1 were identified to increase in the phosphorylation of 4E-BPs and increase in the phosphorylation of S6 (
[0126] In brief, samples were obtained by resecting lesion tissues from the TSC2, FCD254, and HME255 patients selected in Example 1-1 and subjected to immunofluorescence staining. Samples were obtained by resecting lesion tissues from patients suffering from the diseases and subjected to immunofluorescence staining. The immunofluorescence-stained tissues were quantitated for p-4E-BPs-positive or p-S6-positive cells among NeuN-positive neuronal cells in the average of 2-5 cortical regions, and the measurements are expressed as percentages in
[0127] For mouse brain blocks, a brain tissue was harvested at the time of investigation and fixed in freshly prepared phosphate-buffered 4% paraformaldehyde for 2 hours, cryoprotected overnight in 30% buffered sucrose, frozen in OCT on thy ice, and stored at −80° C. Cryostat-cut sections (20-μm thick) were collected and placed on glass slides.
[0128] Tissue sections were blocked in phosphate buffered saline (PBS)-GT (0.2% gelatin and 0.2% Triton X-100 in PBS) for 1 hour at room temperature, incubated in a diluted primary antibody in blocking buffer at 4° C. overnight, and washed in PBS (3×5 minutes), followed by reaction with a diluted secondary antibody in blocking buffer for 1 hour at room temperature. After an additional round of washing, the coverslips were mounted onto a mounting solution containing DAPI (P36931, Life Technologies).
[0129] Among the antibodies used, there were antibodies against phosphorylated S6 (Ser240/244) (Cell signaling, 5364, 1:800), phosphorylated 4E-BP (Thr37/46) (Cell Signaling, 2855, 1:200), and NeuN (Millipore, MAB377, 1:100). The samples were washed with PBS and stained with the following secondary antibodies: Alexa Fluor 594-conjugated goat anti-rabbit antibody (1:200 diluted, A11012, Thermo scientific) and Alexa Fluor 488-conjugated goat anti-rabbit antibody (1:200 diluted; A11001, Thermo scientific). A mounting solution containing DAPI (P36931, Life Technology) was used for nuclear staining. Confocal images were obtained with a Zeiss LSM780 or LSM800 (Carl Zeiss) confocal microscope with sequential acquisition set at a resolution of 2048×2048 pixels.
[0130] Cells positive for NeuN, phosphorylated S6 (Ser240/244), and phosphorylated 4E-BP (Thr37/46) were counted using a ×10 or ×20 objective lens. Four or five fields were acquired per a subject.
[0131]
[0132] When activated, mTOR, which is a kinase targeting 4E-BP1/2/3(4E-BPs) and S6K, induces the phosphorylation of 4E-BP1/2/3 and S6. When phosphorylated, 4E-BP1/2/3 is inactivated, leading to the activation of eIF4E on which 4E-BP1/2/3(4E-BPs) acts as a repressor. Meanwhile, eIF4B is activated to help the function of eIF4E. S6K phosphorylates S6 and eIF4B which, in turn, increases the activity of eIF4E. eIF4B increases the activity of the eIF4F complex which includes eIF4E as a key component.
[0133] 1-4: Western Blot Analysis for Expression of ADK, CREB1, and IRSp53 in Patient Sample
[0134] eIF4E hyperactivation resulted in an increase in the expression of the eIF4E activation-sensitive genes ADK, CREB1, and IRSp53 in the FMCD epilepsy patients of Example 1-1, as measured by translatome profiling analysis (
[0135] A translatome is composed of all mRNA fragments that are translated in a moment or condition in a single cell. Usually, a translatome profiling or ribosome profiling technique is used to acquire the translatome information. Tranlsatome profiling is a technique for analyzing the translation of mRNA into proteins at the genomic level.
[0136]
[0137] Antibodies used in this analysis included antibodies against ADK (Human atlas, HPA038409, 1:500), IRSp53 (Novus, NBP1-88711, 1:1000), CREB1 (Cell signaling, 9197, 1:1000), and phosphorylated S6 (Ser240/244) (Cell signaling, 5364, 1:1000).
[0138] In FMCD epilepsy patients, eIF4E hyperactivation was observed to increase expression levels of the eIF4E hyperactivation-sensitive genes ADK, CREB1, and IRSp53 as analyzed by translatome profiling (
[0139] 1-5: Immunofluorescence Analysis for Expression of ADK, CREB1, and IRSp53 in Patient Sample
[0140] Using immunofluorescence staining, the FMCD epilepsy patients (TSC2, FCD254, and HME255) in Example 1-1 were identified to increase in the expression of ADK, IRSp53, and CREB (
[0141] Samples were obtained by resecting lesion tissues from the TSC2, FCD254, and HME255 patients selected in Example 1-1 and subjected to immunofluorescence staining in the same manner as in Example 1-3. Samples were obtained by resecting lesion tissues from patients suffering from the diseases and subjected to immunofluorescence staining. The immunofluorescence-stained tissues were quantitated for ADK-, IRSp53-, or CREB1-positive cells among NeuN-positive neuronal cells in the average of 2-5 cortical regions, and the measurements are expressed as percentages in
[0142] Among the antibodies used, there were antibodies against NeuN (Millipore, MAB377, 1:100), ADK (Human atlas, HPA038409, 1:200), CREB1 (Cell signaling, 9197, 1:800), and IRSp53 (Novus, NBP1-88711, 1:100). Cells positive for NeuN, ADK, CREB1, and IRSp53 were counted using a ×10 or ×20 objective lens. Four or five fields were acquired per subject.
[0143] In
[0144] 1-6: Comparison Between Patients and Animal Models
[0145] U.S. Pat. No. 9,629,346 discloses that FCD type II animal models having brain somatic mutations in mTOR (C1483Y or L2427P) exhibited mTOR hyperactivation through the phosphorylation of S6 protein.
[0146] The results, obtained in Example 1-3, for the phosphorylation of 4E-BPs and the activation of S6K in the tissues of the FMCD patients (
[0147] In mice at embryonic day 18 (E18) and at postnatal days 56 to 120 (P56-P120), which had undergone in-utero electroporation at embryonic day 14 (E14), the mTOR hyperactivation due to mTOR mutation greatly increased levels of phosphorylated S6 protein and phosphorylated 4E-BP protein (
[0148] Video-Electroencephalography monitoring was carried out on the animal models. EEG signals from epidural electrodes positioned on the frontal lobes (AP 2.8 mm, ML ±1.5 mm) and temporal lobes (anterior to posterior—2.4 mm, medial to lateral ±2.4 mm) were recorded using the cerebellum as a reference. After more than 10 days of recovery from the surgery, EEG signals were recorded for more than 2 days (12 hours per day) (
TABLE-US-00005 TABLE 5 No. of No. of mice Group GFP + pups with seizure % Wild type 8 0 0 p.Cys1483Tyr 15 14 93.3 p.Leu2427Pro 23 21 91.3
[0149] As can be seen in
<EXAMPLE 2> Prevention of Epilepsy Onset Through eIF4E Downregulation with sheIF4E (Genetic Inhibition of eIF4E)
[0150] 2-1: Preparation of eIF4E-Downregulated Animal Model Using sheIF4E
[0151] An examination was made to see whether the translation dysregulation mediated by eIF4F activating mutation induces the major phenotypes of FMCD, including epilepsy, cytomegalic dysmorphic neurons, and cortical dyslamination.
[0152] To this end, in vivo knockdown of eIF4E, which is a key component of the eIF4F complex, was performed to reduce eIF4F activity in FMCD mice via in utero electroporation of mTOR mutant or wild-type constructs co-expressing scrambled shRNAs (shScramble) or shRNAs against eIF4E (
[0153] In brief, an FMCD epilepsy animal model for use in evaluating a therapeutic effect was prepared using a vector carrying mTOR mutation (C1483Y or L2427P) in the same manner in the disclosure of U.S. Pat. No. 9,629,346 on the FCD type II animal model of brain somatic mutation, wherein an shRNA sequence responsible for the translational downregulation of eIF4E was inserted into the pCIG-mTOR mutant-IRES-EGFP vector to construct a recombinant vector (pCIG-mTOR mutant-IRES-EGFP; mU6-sheIF4E).
[0154] In detail, for use in preparing a FCD type II animal model, a recombinant vector was constructed by adding a sheIF4E sequence to the backside sequence of pCIG-mTOR-IRES-EGFP plasmid. shScramble or sheIF4E sequence was obtained with pSicoR vector. pSicoR vector was digested with restriction enzymes HpaI and XhoI. The sequence of shRNA used is as follows. For comparison with shRNA, shScramble was expressed. An RNA transcript from a sense strand is required in order for shRNA to function. Thus, an anti-sense strand is incorporated upon construction of a vector to give double-stranded sequence from which the sense strand is expressed. The sequences are listed in Table 6, below.
[0155] The sheIF4E consists of a sense sequence (SEQ ID NO: 203) including CGATTGATCTCTAAGTTTGAT (SEQ ID NO: 202), which binds complementarily with a target region, and an antisense sequence (SEQ ID NO: 204). The shScramble sequence consists of a sense sequence (SEQ ID NO: 206) including GGAATCTCATTCGATGCAT (SEQ ID NO: 205), which binds complementarily to a target region, and an antisense sequence (SEQ ID NO: 207).
TABLE-US-00006 TABLE 6 SEQ ID NO name Nucleotide sequence (5′->3′) 202 SheIF4E CGATTGATCTCTAAGTTTGAT 203 sheIF4E T-CGATTGATCTCTAAGTTTGAT- sense TTCAAGAGA- strand ATCAAACTTAGAGATCAATCG- TTTTTTCTCGA 204 sheIF4E TCGAGAAAAAA- anti-sense CGATTGATCTCTAAGTTTGAT-TCTCTTGAA- strand ATCAAACTTAGAGATCAATCG-A 205 shScramble GGAATCTCATTCGATGCAT 206 shScramble T-GGAATCTCATTCGATGCAT-TTCAAGAGA- sense ATGCATCGAATGAGATTCC-TTTTTTCTCGA strand 207 shScramble TCGAGAAAAAA-GGAATCTCATTCGATGCAT- anti-sense TCTCTTGAA-ATGCATCGAATGAGATTCC-A strand
[0156] The pSicoR vector digested with HpaI and XhoI restriction enzymes was ligated with the shScramble or the sheIF4E sequence in the presence of ligase to construct pSicoR-shScramble and pSicoR-sheIF4E vectors, respectively. Neuro2A cells were cultured and transfected with pSicoR to evaluate the translational downregulation of eIF4E in the same manner as in Example 1.2.
[0157] From the pSicoR-shScramble vector and the pSicoR-sheIF4E vector, shScramble and sheIF4E were respectively amplified, together with the mU6 promoter, by PCR using the following primers:
TABLE-US-00007 Forward primer (SEQ ID NO: 208): ggccgaggcctcctgggcccgctctagagatccgac Reverse primer (SEQ ID NO: 209): cgagtactaggatccattaggcgg
[0158] The PCR products (shScramble and sheIF4E sequences), each including the mU6 promoter, were digested with SfiI restriction enzyme. pCIG-mTOR mutant-IRES-EGFP vector was cut with PsiI and SfiI restriction enzymes. The digested pCIG-mTOR mutant-IRES- as ligated with the digested shScramble or sheIF4E each including the mU6 promoter, using a ligase. The sheIF4E sequence-added vector pCIG-mTOR mutant-IRES-EGFP; mU6-sheIF4E plasmid was constructed using the method described above.
[0159] As will be explained below,
[0160] 2-2: Efficient Knockdown of eIF4E and Effect of In-Vivo Knockdown of eIF4E on Expression of ADK, IRSp53, and CREB1
[0161] For the animal model, prepared in Example 2-1, in which eIF4E was knock-downed using sheIF4E, after embryos that had been electroporated with a plasmid carrying an mTOR mutant gene at embryonic day 14 (E14), in the same manner as in U.S. Pat. No. 9,629,346, were born, the mice expressing fluorescence were screened by flashlight (Electron Microscopy Science, USA).
[0162] In this regard, immunofluorescence staining for eIF4E was performed on the mice, showing a reduced expression level of eIF4E and demonstrating the function of the model (
[0163] In detail, efficient knockdown of eIF4E by sheIF4E was validated by Western blot analysis in substantially the same manner as in Example 1 (
[0164] Immunostaining for eIF4E was performed in substantially the same manner as in Example 1 on the mice, showing that eIF4E expression was significantly reduced in sheIF4E-expressing neurons (
[0165] Therefore, the present inventors performed additional immunostaining in order to investigate in vivo knockdown effect on the expression of ADK, IRSp53, and CREB1 in the FMCD mice, and confirmed significant reduced expression of the genes (
[0166] 2-3: Incidence of Epilepsy Onset in Animal Model Expressing shScramble
[0167] In FMCD animal models, the onset of epilepsy starts at postnatal day 21 on average and has been completed within postnatal day 50. Video EGG monitoring was conducted from 3 weeks after birth. EGG signals were recorded for 12 hours per day three times in a week from postnatal day 21 to postnatal day 120. From the 12-hour video recordings, the number and length of seizures were measured.
[0168] For this experiment, the animal models expressing shScramble, established in Example 2-1, were used. Seizure was detected in 19 of 20 models having mTOR p.C1483Y mutation and in 23 of 25 models having mTOR p.L2427P mutation. Seizure was observed from the 12-hours video recordings taken from postnatal day 21 to postnatal day 120 (
[0169] 2-4: Prevention of Epilepsy Incidence in Animal Model with sheIF4E-Mediated Knockdown Against eIF4E Therein (Seizure Measurement)
[0170] The eIF4E-downregulated animal models established in Example 2-1 were video recorded for 12 hours a day three times in a week from postnatal day 21 to postnatal day 120, using a lifecam. From the 12-hours video recordings, the number and length of seizures were measured (
[0171] From the video recordings taken until postnatal day 120 for animal models with sheIF4E-mediated knockdown of eIF4E, as shown in
[0172] Although epilepsy was generated, the frequency and time of seizure were remarkably decreased. In the FMCD animal models, intractable epilepsy significantly decreased in seizure frequency and time when eIF4E-targeting shRNA was expressed to reduce the expression of eIF4E in mTOR mutant-expressing cells. In the FMCD epilepsy animal models, intractable epilepsy significantly decreased in seizure frequency and time when eIF4E-targeting shRNA was expressed to reduce the expression of eIF4E in mTOR mutant-expressing cells.
[0173] 2-5: Analysis for Cortical Dysplasia, Neuron Size, and Synaptic Spine Density in Animal Model with sheIF4E-Mediated Downregulation of eIF4E
[0174] Animal models generated with pCIG-mTOR mutant-IRES-EGFP; mU6 sheIF4E vector in Example 2-1 had mTOR mutant-expressing neurons in which the expression of eIF4E protein was downregulated.
[0175] Then, mice born following the electroporation of Example 1-6 were analyzed for neuronal cell size and synaptic spine density. Neuronal cell size was measured in ImageJ software (http://rsbweb.nih.gov/ij/). Synaptic spines were counted using a 63× objective lens. Ten basal dendrites were acquired per subject, and measured in electroporated cells expressing a GFP reporter, using manual counting. For neuronal cell size (
[0176] In addition, for cortical dysplasia (
[0177] Therefore, it was observed that the expression downregulation of eIF4E could reduce cortical dysplasia caused by the mTOR pathway activating mutation found in intractable epilepsy patients and the expression regulation of eIF4E could be a therapeutic target for cortical dysplasia.
[0178] 2-6: Effect of In Vivo Knockdown of eIF4E
[0179] This experiment was conducted to examine whether the sheIF4E-mediated in-vivo knockdown of eIF4E in Example 2-1 could alleviate the major phenotypes of FMCD. sheIF4E-mediated eIF4E knockdown was found to successfully rescue all of the pathological phenotypes in both mTOR p.Cys1483Tyr and p.Leu2427Pro mice, compared to the shScramble mice (
[0180] In detail, it was found that eIF4E knockdown almost completely rescued spontaneous seizures observed in the FMCD epilepsy mice (
[0181] 2-7: Rescuing Effect of sheIF4E-Mediated In-Vivo Knockdown of eIF4E
[0182] In the FMCD animal models established with the pCIG-mTOR mutant-IRES-EGFP; mU6 sheIF4E vector of Example 2-1, neuronal cells exhibited a downregulated expression level of eIF4E protein. In order to examine whether sheIF4E-mediated in-vivo knockdown of eIF4E led to the expression downregulation of eIF4E-sensitive genes, expression of eIF4E-sensitive genes was analyzed by immunofluorescence. The immunofluorescence results are depicted in
[0183] As shown in
<EXAMPLE 3> Treatment of Epilepsy with Drug in Animal Model (Pharmacological Inhibition of eIF4E)
[0184] In this experiment, metformin was intraperitoneally injected at a dose of 200 m/kg into the FMCD animal models of Example 1 from P14 to P56 for early treatment and from P84 to P114 for late treatment. Thereafter, 12-hour recording and video-EEG analysis demonstrated that the early treatment with metformin prevented seizure onset and the late treatment suppressed seizure frequency in the FMCD mice (
[0185] Accordingly, these results showed that the increased activity of eIF4F leads to the phenotypes of FMCD via the increased translation of the mTOR activation-sensitive genes (e.g., ADK, IRSp53, and CREB1) and that epileptic seizures could be prevented through eIF4E inhibition by metformin.
<EXAMPLE 4> In Vitro Assay for Efficacy of eIF4E Inhibitor
[0186] 4-1: ASO Design and Construction
[0187] ASO sequences that effectuate prophylactic or therapeutic effects on the epilepsy caused by upregulated eIF4E expression, activity, or level were acquired by in-vitro screening. Selection was made of ASO therapeutic sequences highly inhibitory of eIF4E expression.
[0188] In this regard, 16- to 20-mer ASO sequences capable binding complementarily to pre-mRNA including the UTR, intron, and exon of human eIF4E gene, using the BLAST program.
[0189] Briefly, candidate ASO sequences each had a phosphorothioate bond for every inter-nucleoside bond. For 20-mer ASO, each of the nucleotides at positions 1 to 5 and 16 to 20 in the 5′ to 3′ translation direction had the 2′-O-(2-methoxyethyl) sugar while the nucleotides at positions 6 to 15 were each modified into 2′-deoxynucleotide, with 5-methylcytosine being employed instead of all cytosine residues. The 16-mer ASO was substantially the same as the 20-mer ASO, with the exception that nucleotides at positions 1 to 3 and 14 to 16 in the 5′ to 3′ direction had 2′-O-(2-methoxyethyl) sugar. In addition, the phosphodiester linkage was chemically modified into a phosphothioester bond.
[0190] 4-2: ASO Screening by Western Blot Analysis
[0191] The designed eIF4E inhibiting ASO was constructed by Integrated DNA Technologies (IDT) and purified through HPLC and Na+ exchange purification.
[0192] For ASO screening, first, MO candidates were transfected into the human cell lines HEK293T (Human) or the mouse cell line Neuro2A (mouse) with the aid of Lipofectamine 2000. The cells were harvested 72 hours after ASO transfection and then lysed to extract proteins which were analyzed for eIF4E expression by western blotting. Efficient ASO sequences that regulate eIF4E were identified by in-vitro screening. eIF4E protein expression levels in each cell line were normalized to α-tubulin and quantified relative to the control (scrambled ASO-1: CTCAGTAACAGTGACACCAG (SEQ ID NO: 201). Expression levels of eIF4E relative to the control are depicted (
[0193] For the western blots of
[0194] 4-3: ASO Screening by Real-Time PCR
[0195] In Example 4-2, proteins extracted from cells were analyzed for eIF4E expression by western blotting to screen ASO that regulates eIF4E expression. In this Example, RNA was extracted from cells and analyzed for eIF4E mRNA transcription by real-time PCR so as to screen ASO that regulates eIF4E expression.
[0196] In an alternative approach for screening the designed ASO candidates, the human cell line HEK293T cells (human) were cultured on 96-well culture plates for 24 hours and then transfected with ASO candidates with the aid of iNfect transfection reagent (iNtRON, 15081). Twenty four hours after transfection, the cells were harvested and subjected to lysis and RNA extraction using SuperPrep™ II Cell Lysis & RT Kit reagent (Toyobo, SCQ-401). From the RNA thus obtained, cDNA was synthesized by reverse transcription PCR. Real-time PCR was performed in CXF384 Real-Time System (Bio-Rad) with SYBR green real-time PCR master mix (Toyobo, QPK-201). Forward and reverse PCR primer sequences for eIF4E and GAPDH are as follows:
TABLE-US-00008 EIF4E forward primer (SEQ ID NO: 210): TGGCGACTGTCGAACCG EIF4E reverse primer (SEQ ID NO: 211): AGATTCCGTTTTCTCCTCTTCTGTAG GAPDH forward primer (SEQ ID NO: 212): GAAGGTGAAGGTCGGAGTCAACG GAPDH forward primer (SEQ ID NO: 213): GAAGATGGTGATGGGATTTCC
[0197] The real-time PCR conditions in the CXF384 Real-Time System were as follows: 95° C. for 1 min, then 95° C. for 15 sec, 59.5° C. for 20 sec, and 72° C. for 30 sec for 39 cycles. Each sample was analyzed in triplicates. Relative mRNA expression was normalized to the expression level using GAPDH as an internal control and was evaluated using the 2.sup.−ΔΔCq method. eIF4E expression levels are expressed as relative ratios compared with the control scrambled ASO-1 (CTCAGTAACAGTGACACCAG: (SEQ ID NO: 201)) in
[0198] Through the screening method, ASO sequences that exhibited high inhibitory activity against eIF4E expression, compared to the control scrambled ASO-1 (CTCAGTAACAGTGACACCAG; SEQ ID NO: 201), were selected. The selected ASO sequences are given in Table 2.
[0199] 4-4: Secondary Selection of ASO
[0200] From the primarily selected ASO as eIF4E inhibitors in Table 2, selection was made of ASO that reduced eIF4E expression to the degree as great as or greater than that of SEQ ID NO: 75 (ASO-1), for example, ASO that allowed eIF4E mRNA expression in a quantitatively predetermined range relative to the eIF4E expression level of ASO #75 (ASO-1), (e.g., eIF4E mRNA expression level of 125% or less, 120% or less, 115% or less, 110% or less, or 100% or less relative to that of ASO #75). Moreover, more preferable ASO was selected on the basis of additional criteria such as off-target and/or mismatch base pairing, and the results are given in Table 7, below.
[0201] In Table 7, the number of off-target genes was the number of target genes other than eIF4E, which are coincident except for differing by 1, 2, or 3 nucleotides on the corresponding ASO sequences when an in-silico method was performed on each of the selected ASO sequences; and the eIF4E expression represents the mRNA expression level measured by real-time PCR in the same manner as in Example 4-3 as % inhibition of each ASO relative to ASO #75.
TABLE-US-00009 TABLE 7 SEQ Number of gene in the Off target Expression level of eIF4E(%) ID No 1 bp 2 bp 3 bp compared to ASO#75 #16 0 2 59 93% #20 0 5 70 71% #21 0 6 78 68% #27 0 1 64 97% #28 2 9 132 94% #35 0 1 18 72% #75 0 3 67 100% #77 0 2 48 121% #89 4 N/D N/D 65% #132 2 14 5 45% #143 0 3 27 45% #147 0 5 18 91% #149 0 3 29 73% #161 2 5 24 122% #162 2 4 25 63% #171 0 8 25 59% #178 0 7 40 38% #179 0 5 34 92% #180 1 4 31 70% #182 0 0 37 99% #183 0 4 9 89% #184 0 3 27 82%
[0202] 4-5: Common Motif of ASO Sequences
[0203] For the sequences listed in Table 2, Multiple Em for motif elicitation (MEME, http://meme-suite.org/tools/meme) was performed using MEME browser application program (version 5.1.1) to analyze the ASO sequences highly inhibitory of eIF4E expression for common motifs (Bailey T L, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc. Second Int. Conf. Intell. Syst. Mol. Biol. 1994;28-36).
[0204] Through the multiple Em for motif elicitation (MEME) analysis for some of the selected ASO sequences in Example 4-4, it was found that a specific common motif was enriched with statistical significance.
[0205]
[0206] 4-6: Inhibitory Concentration (IC.sub.50) Against eIF4E mRNA (Real-Time PCR)
[0207] The ASO sequences, acquired by the in-vitro screening method, which effectively inhibit eIF4E expression, that is, ASO #21, ASO #27, ASO #35, ASO #75 (ASO-1), ASO #77 (ASO-3), and ASO #182 were analyzed for inhibitory concentration (IC.sub.50) against eIF4E mRNA expression.
[0208] In order to calculate IC.sub.50 values for ASO sequences, ASO candidates are transfected at different concentrations (20 nM, 80 nM, 320 nM) into the human cell line HEK293T (human) with the aid of iN-fect™ in vitro transfection reagent (15081, iNtRON, Republic of Korea). Twenty four hours after ASO transfection, the cells were harvested and analyzed for eIF4E mRNA expression reduction by real-time PCR. Relative eIF4E mRNA expression was normalized to the expression level using GAPDH as an internal control and was evaluated using the 2.sup.−ΔΔCq method.
[0209] As an analysis result for the HEK293T cells, eIF4E mRNA expression was inhibited by ASO #75, ASO #77, ASO #21, ASO #27, and ASO #35 at all of the doses, compared to the mismatch ASO: GATCCTTTGTTAATGTTACA (SEQ ID NO: 214), which is the same as ASO #77 with the exception that bases CACC at positions 8-9-10-11 was changed to TGTT. For comparison of inhibitory concentrations (IC.sub.50) among ASO candidates, a dose-response curve was derived by normalized nonlinear regression using Prism8 program (GraphPad Software, USA) (
[0210] The data of IC.sub.50 showed that the inhibitory potency against eIF4E mRNA expression in HEK293T cells was decreased in the order of ASO #35 (IC.sub.50=22.77 nM), ASO #77 (IC.sub.50=53.82 nM), ASO #21 (IC.sub.50=86.69 nM), ASO #182 (IC.sub.50=91.07 nM), ASO #27 (IC.sub.50=92.45 nM), and ASO #75 (IC.sub.50=93.93 nM).
[0211] 4-7: Expression Level of Off-Target Gene
[0212] This experiment was conducted to examine whether ASO #35 and ASO #75 in Table 2 had inhibitory activity against the expression of off-target genes.
[0213] In Silico analysis identified the following off-target genes: one off-target gene (ERBB4) with two nucleotide mismatches with ASO #35; and four off-target genes (TNFAIP8L3, STK32A, TTPA, TTC28) with two nucleotide mismatches with ASO #75. Off-target gene analysis was performed on ERBB4 to ASO #35 and TTC28 (Tetratricopeptide repeat domain 28) to ASO #75.
[0214] Briefly, ASO #35 or ASO #1 were transfected at various doses (5 nM, 20 nM, 80 nM, 320 nM, and 1280 nM) into HEK293T cells (human), with the aid of iN-fect™ in vitro transfection reagent (15081, iNtRON, Republic of Korea). Twenty four hours after ASO transfection, the cells were harvested and subjected to lysis and RNA extraction using SuperPrep™ II Cell Lysis & RT Kit reagent (Toyobo, SCQ-401). Then, real-time PCR for ERBB4 and TTC28 mRNA expression was performed in CXF384 Touch Real-Time PCR Detection System (Bio-Rad, USA) with SYBR® Green Realtime PCR Master Mix (QPK-201, TOYOBO, Japan). Real-time PCR conditions using CXF384 Touch Real-Time PCR Detection System were as follows: 95° C. for 1 min, followed by 40 cycles of 95° C. for 15 sec, 59.5° C. for 20 sec, and 72° C. for 30 sec. Each sample was analyzed in triplicates. Relative mRNA expression of ERBB4 and TTC28 was normalized to the expression level using GAPDH as an internal control and was evaluated using the 2.sup.−ΔΔCq method. eIF4E and GAPDH primers for real-time PCR were the same as in Example 4-3. Forward and reverse primers for ERBB4 and TTC28 genes were as follows:
TABLE-US-00010 ERBB4 forward primer (SEQ ID NO: 215): CAGTCAGTGTGTGCAGGAAC ERBB4 reverse primer (SEQ ID NO: 216): AGCCTGTGACTTCTCGAACA TTC28 forward primer (SEQ ID NO: 217): CTCATGGGAATCTGGGCTCT TTC28 reverse primer (SEQ ID NO: 218): TGATGAAGCTGCCTCTCGAT
[0215] In
[0216] 4-8: Chemical Modification (cEt/LNA)
[0217] ASO with constrained ethyl (cEt) nucleotide modification is generally termed 2.5 ASO. A cEt-modified sugar refers to bicyclic sugar moiety comprising a bridge between 4′-carbon and 2′-carbon (4′-CH(CH.sub.3)—O-2′). In addition, for a chemically modified structure, locked nucleic acid (LNA), which is termed third generation analogue for MO, comprises a ribose having a modified structure locked by an extra bridge between 4′ carbon and 2′ oxygen in the nucleotide. LNA is known as an RNA analogue enhancing Watson-Crick base pairing intensity.
[0218] eIF4E inhibiting ASOs modified to have cEt nucleotides at positions 1-5 and 16-20 and a phosphothioate bond for every internucleoside linkage with respect to ASO sequences #21, #35, and #78 of Example 4-1 were synthesized by Bio-Synthesis. eIF4E inhibiting ASOs modified to have LNA nucleotides at positions 1-5 and 16-20 and a phosphothioate bond for every inter-nucleoside linkage with respect to ASO sequences #77, #27, and #35 were synthesized by IDT. All of the ASOs synthesized were purified by HPLC and Na+ exchange purification. The mismatch control (MM) accounts for the control ASO of GATCCTTTGTTAATGTTACA (SEQ ID NO: 214) in a 2′ MOE gapmer structure having TGT instead of the bases CAC at positions 8-9-10 on the sequence of ASO #77.
[0219] As eIF4E inhibitors, ASOs chemically modified with cEt or LNA were analyzed for inhibitory activity against eIF4E expression. In this regard, ASO candidates were transtected into the human cell line HEK293T (human), using iNfect transfection reagent (iNtRON, 15081). Twenty four hours after transfection, the cells were harvested and analyzed for inhibitory activity against eIF4E expression by real-time PCR Relative expression levels are quantitatively expressed as ratios, compared to the control ASO having 3 nucleotide mismatches with eIF4E (
<EXAMPLE 5> Treatment of FMCD Epilepsy Animal Model with ASO
[0220] 5-1: Treatment of Epilepsy Through eIF4E Expression Reduction in Animal Model (Seizure Monitoring)
[0221] ASO #75 and ASO #77 of Table 2, constructed in Example 4-1, were observed to reduce eIF4E expression in animal models.
[0222] For this experiment, animal models established using pCIG-mTOR p.C1483Y-IRES-EGFP and pCIG-mTOR p.L2427P-IRES-EGFP of Example 1 were used while animal models established with pCIG-mTOR (WT)-IRES-EGFP (mTOR p.C1483Y or mTOR p.L2427P) served as a control. The ASOs were each intracerebroventricularly injected (ICV injection) at a dose of 100-500 μg to the brains of the mice that had been identified to undergo epileptic seizure. From day 3 after ASO injection to up to day 70, 12-hour video were recorded for seizure monitoring 2-3 times a week per mouse.
[0223] From the experiment result, it was found that the injection of ASO #75 (ASO-1) or ASO #77 (ASO-3) remarkably reduced seizure frequency in the epilepsy models (mTOR p.C1483Y or mTOR p.L2427P)).
[0224] After intraventricular injection of the ASO candidates to the animal models, eIF4E expression was reduced in the cerebral cortex, the cerebellum, and the spinal cord, with the consequent reduction in seizure frequency.
[0225] 5-2: Distribution of ASO in Brain Cells
[0226] In order to examine whether brain cells uptook ASO in practice, cy3 (fluorescent dye)-labeled ASO (cy3-ASO) was intracerebroventricularly injected and analyzed for cellular distribution.
[0227] Mice (C57BL/6J) (Damul Science) or the animal models established with pCIG-mTOR mutant-IRES-EGFP in Example 1 were anesthetized with isoflurane (0.4 L/min of oxygen and isoflurane vaporizer gauge 2 during surgery operation). Surgical incision was made from the dorsal neck to the glabella. The cranium thus exposed was wiped with a cotton swab.
[0228] A steam-sterilized 26G syringe was sterilized three times with 70% ethanol and additionally once with distilled water. The syringe needle was positioned at the site AP −0.3 mm from the bregma and ML +1.0 mm. The syringe needle was inserted DL −3.0 mm from the bregma and positioned at the lateral ventricle. Three minutes after needle positioning, ASO was injected at a rate of 0.5 μl/sec. The syringe was left for 3 min after injection and then removed. A cotton swab was pressed for 1 min against the injected site and the skin was sutured.
[0229] Results of intracerebroventricular injection of ASO to mice are depicted in
[0230]
[0231] 5-3 Expression Recovery of ADK, IRSp53, and CREB1 and Reduction of Intracellular eIF4E Expression in Animal Model by ASO Injection
[0232] Week 4-5 after intracerebroventricular injection of ASO into the animal models established using pCIG-mTOR mutant-IRES-EGFP vector of Example 1, the brain was removed, fixed, sectioned, and immunostained.
[0233] Immunostaining with antibodies against ADK, CREB1, IRSp53, and eIF4E and Imaging with fluorescence were conducted in the same manner as in Example 2.
[0234]
[0235]
[0236] 5-4: Analysis of Cortical Dysplasia and Neuronal Cell Size in Animal Model with eIF4E Expression Reduced by ICV Injection of ASO
[0237] Week 4-5 after intracerebroventricular injection of ASO into the FMCD animal models established using pCIG-mTOR mutant-IRES-EGFP vector of Example 1, the brain was removed, fixed, sectioned, and immunostained. For neuronal cell size (
[0238]
<EXAMPLE 6> Behavioral Assay of Normal Animal According to ASO Injection
[0239] 6-1: Experimental Mouse and ASO
[0240] A therapeutic effect on behavioral abnormality that occurred in control normal models (C57BL/6J mice) upon ASO injection was examined. In this regard, ASO was administered by ICV injection. The ASO used in this experiment was ASO #77.
[0241] The ASO-injected control animal model was evaluated for behavioral abnormality in the manners as in Examples 6-2 and 6-10. The results of behavioral abnormality assay according to ASO injection to the mice are depicted in
[0242] 6-2: Body Weight and Temperature Measurement
[0243] Mice weighed every week after ASO injection.
[0244] The body temperature was measured after anesthesia of the mice. Briefly, mice were placed within an anesthesia induction chamber. Anesthesia was induced and maintained for 2 min with 0.4 L/min of oxygen and isoflurane. During anesthetic maintenance, rectal temperatures were measured using rodent warmer xl (STOELTING). The rectal temperature probe was inserted 2 cm into rectum, 10 seconds after which temperatures were measured.
[0245]
[0246] 6-3: Mouse Handling
[0247] Mouse handling was performed for 10 min at the same time every day for 5 days before behavioral test so that the mice were allowed to feel secure with the handler. In order for the mice to receive minimal stress, a one day interval was posed between different behavioral tests. All of the behavioral tests were analyzed in double-blind trials.
[0248] 6-4: Open Field Test
[0249] Before behavioral tests, mice underwent a habituation procedure for 10 min in the test space. The mouse was placed in a box with a dimension of 40×40 (cm), allowed to freely move therein, and measured for open field activity for 10 min. Behaviors were recorded and analyzed using EthoVision XT (Noldus). The mice were returned back to their home cages and the experiment apparatus was washed with 70% EtOH.
[0250]
[0251] 6-5: Light & Dark Box Test
[0252] Before each experiment, mice were subjected to a habituation procedure for 10 min in a test space. Each mouse was placed in a light & dark box with a dimension of 20×20 (cm) and allowed to freely move for 10 min therein. Behaviors were recorded and analyzed using EthoVision XT (Noldus). The mice were returned back to their home cages and the experiment apparatus was washed with 70% EtOH.
[0253]
[0254] 6-6: Social Avoidance Test
[0255] A video tracking system was used to score approach-avoidance behaviors toward an unfamiliar social target. The arena was a black box (400×400 mm). Each experimental mouse was introduced into the black box and its trajectory was tracked for two consecutive sessions of 2.5 min. During the first session (“no target”) the box contained an empty perforated cage (10×6.5 cm). During the second session (“target”), the conditions were identical except that a social target (an unfamiliar CD1 mouse) had been introduced into the cage. Between the 2 sessions, the experimental mouse was removed from the arena, and was placed back into its home cage for one min. The video tracking data from both the “no target” and “target” conditions were used to determine the time spent by the experimental mouse in the “interaction zone”, which was a corridor surrounding the cage.
[0256]
[0257] 6-7: 3-Chamber Test (Social Interaction Test)
[0258] The 3-Chamber test measures social interaction and preference for social novelty. This apparatus consisted of three chambers with dimensions of 12×20×26 cm for the center chamber and dimensions of 14×20×26 cm for the opposite side chambers. Each of the opposite side chambers included a plastic cage (11 cm in diameter, 2.15 cm in height) for an object or stranger mouse in a corner. This experiment consisted of three sessions of habituation (10 min), exploring object/mouse (10 min), and exploring familiar/new mouse (10 min). In the second session, a WT stranger mouse was randomly placed in a plastic cage while the opposite plastic cage was empty. The mouse was allowed to freely explore the whole apparatus. The time spent in each chamber was measured and then used for the subsequent social interaction test. In the last session, a new WT stranger was placed in the empty plastic cage.
[0259]
[0260] 6-8: Marble Burying Test
[0261] A general mouse cage covered with a filter-equipped lid was used. Fresh bedding free of mouse smells was evenly laid to the height of 5 cm in each cage. Glass marbles, each weighing 5 g with a diameter of 15 mm, were arranged in six rows of four on the bedding. The marbles were cleaned with a detergent and washed with deionized water. A mouse was placed in the cage. Twenty minutes after the cage was covered with the lid, buried marbles were counted. A marble was considered to be buried when half of its height was hidden in the bedding.
[0262]
[0263] 6-9: Sucrose Preference Test
[0264] Each of mice was habituated for 3-5 days in a cage with two selectable water bottles presented. Thereafter, the mice were each placed in the same cage as the habituation cage at the day of experiment. The mice were presented with two dual bottles, one containing tap water and the other containing 1% sucrose solution. Water and sucrose solution intake was measured after 24 hours and sucrose preference was calculated according to volume of sucrose intake/total volume of fluid intake×100%.
[0265]
[0266] <EXAMPLE 7> Assay for Therapeutic Potential of eIF4E Inhibitor on Neuropsychiatric Disorder
[0267] 7-1: Suitability Evaluation of FMCD Animal Model
[0268] The FMCD animal models of Example 1 (mTOR-p.C1483Y, mTOR-p.L2427P) were evaluated for suitability for use in assaying neuropsychiatric disorders that accompany FMCD and epilepsy models.
[0269] The FMCD animal models with epilepsy were subjected to the substantially same behavioral abnormality assay according to FMCD as in Example 6. The results are depicted in
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277] 7-2: Assay for Therapeutic Potential of sheIF4E on Neuropsychiatric Disorder
[0278] Experiments were performed on the FMCD and epilepsy animal models (mTOR-p.C1483Y, mTOR-p.L2427P) of Example 7-1 and the control normal animal models (mTOR-WT). The same sheIF4E as that described in Example 2 was used. Week 2 after sheIF4E injection, the handling was performed in the animals. Week 3 after sheIF4E injection, the animals were subjected to the behavioral tests.
[0279] The epilepsy animal models were subjected to the substantially same behavioral abnormality assay as in Example 6. The results are depicted in
[0280] In
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288] 7-3: Assay for Therapeutic Potential of ASO on Neuropsychiatric Disorder
[0289] Experiments were performed on the FMCD and epilepsy animal models (mTOR-p.C1483Y, mTOR-p.L2427P) of Example 7-1 and the control normal animal models (mTOR-WT). ASO #77, which downregulates the expression of eIF4E, was employed in this experiment.
[0290] Briefly, ASO #77 was administered by ICV injection to the FMCD and epilepsy animal models were generated with the pCIG-mTOR mutant-IRES-EGFP of Example 1. ASO #77 was evaluated for therapeutic potential for neuropsychiatric disorder accompanying the FMCD epilepsy animal models in the substantially same manner as in Example 6.
[0291] Results of the assay for therapeutic potential of ASO on neuropsychiatric disorders of the FMCD animal models according to MO-mediated eIF4E knockdown in the epilepsy model mice are depicted in
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
<EXAMPLE 8> Identification of eIF4E Hyperactivation-Sensitive Gene
[0299] 8-1: Construction of Neuronal Cell Having mTOR Mutation
[0300] Mutant cells in the FMCD animal models of Example 1 were labeled with GFP and the GFP-positive cells were sorted by fluorescence-activated cell sorting (FACS) to acquire mTOR mutant cells.
[0301] In brief, from in utero-electroporated mice, cortical neurons expressing MTOR-WT, MTOR-p.Cys1483Tyr, or MTOR-p.Leu2427Pro, along with GFP reporter, were dissected at E18.5 in Hank's balanced salt solution (Life Technologies) supplemented with 10 mM HEPES (Gibco, 15630-080) and Pen/Strep (Life Technologies, 15140-122). For analysis of protein expression regulation, the medium was added with 100 μg/mL cycloheximide (Millipore, 239763), which is a ribosome elongation inhibitor.
[0302] In order to discriminate mutation-expressing cells, GFP-positive cortical portions were identified from the electroporated regions and excised in Hibernate-E medium (Gibco, A12476-01) supplemented with GlutaMAX4 (Gibco, 35050-061) and B27 (Gibco, 17504-044). GFP-positive cortices were digested in dissection medium containing 0.05% trypsin (Life Technologies, 15090-046) for 30 minutes at 4° C. After digestion, pellets were centrifuged and resuspended three times in Hibernate-E medium supplemented with GlutaMAX-I and B27.
[0303] To dissociate cells, fire-polished Pasteur pipettes (Corning, CO-7095B-9) were used. Sequentially, 100-μm and 40-μm strainers were used to remove large debris. Cell sorting was performed with the BD FACSAria II Flow Cytometer (BD Biosciences) with FITC gating. Sorted cortical neurons were stored at −80° C. for up to 6 months.
[0304] 8-2: Translatome Profiling Using mTOR Mutation-Expressing Cell
[0305] Translatome profiling identified genes that have mRNA translation upregulated by mTOR mutation. mRNA translation of the genes was increased by mTOR mutation. As seen in
[0306] 8-3: Preparation of Ribo-Seq and RNA-Seq Library
[0307] (1) Ribosome Profiling (Ribo-Seq) and RNA Sequencing (RNA-Seq)
[0308] Cells were seeded in 10-cm dishes at 50% confluence. The cells had not reached maximum confluence by the following day. NIH 3T3 cells were treated with 200 nM Torin1 or vehicle, and CRISPR-edited mTOR (G4448A)-pC1483Y NIH 3T3 cells were treated with vehicle for 3 hours. The cells were washed once with ice-cold PBS supplemented with 100 μg/mL cycloheximide and lysed in mammalian polysome buffer (10 mM Tris-HCl at pH 7.4, 5 mM MgCl.sub.2, 100 mM KCl, 2 mM DTT, 1% Triton X-100, 100 μg/mL cycloheximide supplemented with 1 μL, of protease inhibitor cocktail, 2 μL, of RNasin, and 2 μL, of SUPERase) to maintain binding between the ribosomes and mRNA. The samples were incubated for 20 minutes on a rotator to induce cell lysis. For FACS-sorted cortical neurons, the same treatments were applied. The cell lysates were separated into 2 tubes, 75% of the sample for Ribo-Seq and the rest for RNA-Seq, which were used to prepare Ribo-Seq and RNA-Seq libraries, respectively.
[0309] (2) Preparation of Ribo-Seq and RNA-Seq
[0310] For Ribo-seq, the prepared cell lysates were treated with RNase I (Ambion, AM2294) to remove the ribosome-unbound region of mRNA from the ribosome-mRNA complexes. Subsequently, the ribosome-mRNA complexes were purified using Sephacryl S-400 columns (GE Healthcare, 27-5140-01). RNA footprints (i.e., ribosome-bound region of mRNA) were extracted from the sample using TRIzol LS (Ambion, 10296-010). rRNA was removed from the sample using a Ribo-zero rRNA removal kit (Epicentre, RZH110424).
[0311] For RNA-seq, total RNA was purified from the cell lysates using TRIzol LS. Subsequently, the RNA sample was enriched using RNA Clean & Concentrator-5 or -25 (Zymo Research, R1015 or R1017). rRNA was removed using a Ribo-zero rRNA removal kit (Epicentre, RZH110424). After rRNA removal, the sample RNAs were fragmented via alkaline hydrolysis using the NEBNext Magnesium RNA Fragmentation Module (New England BioLabs, E6150S).
[0312] Ribosome footprints (30 nt in size) and RNA fragments (40-60 nt in size) were size-fractionated by Urea-PAGE and purified from the gel elutes.
[0313] (3) Antarctic Phosphatase and PNK Treatment
[0314] RNase I digestion and alkaline hydrolysis left a monophosphate group at the 3′ end of each of the ribosome footprints and RNA fragments, respectively. After removal of the monophosphate group by Antarctic phosphatase (NEB, M0289S), the bare 3′ end was connected to the 5′ end of an adenylated 3′ linker. To this end, the samples were incubated in 20 μl, of 1× reaction mixture containing 1 μL of Antarctic phosphatase for 1 hour at 37° C., and subsequently incubated for 5 minutes at 65° C. to inactivate the enzyme. Following the reaction, the RNAs were incubated in 45 μL of 1× reaction mixture containing 2 of PNK (Takara, 2021A) and 1 of [γ-.sup.32P]-ATP (PerkinElmer, NEG502Z) for 5 minutes at 37° C. to label the RNA with .sup.32P. Following the labeling, 5 μL of 1 mM ATP (NEB, P0756L) was added, and the samples were incubated for 10 minutes at 37° C. to phosphorylate the 5′ end of the RNAs for subsequent 5′ linker ligation. The ribosome footprints and RNA fragments were purified by acidic phenol-mediated RNA extraction and subsequently size-fractionated and purified using Urea-PAGE to remove free ATP.
[0315] (4) Linker Ligation, RT-PCR, and Sequencing
[0316] TruSeq small RNA kits (Illumina, RS-200-0012) were used for 3′ linker, 5′ linker, RT primer, 5′ primer, and 3′ primer ligation.
[0317] To ligate the 3′ linker, 1.5 μL of T4 RNA ligase 2 (Epicentre, LR2D1132K), 1 μL of 10× buffer, 0.5 μL of 3′ linker (RA3, TruSeq Small RNA kit), and 1 μL of SUPERase-In were added to each RNA sample and incubated for 4 hours at 22° C. The linker-ligated RNAs were size-fractionated by Urea-PAGE and then purified from gel elute to remove residual 3′ linker.
[0318] Subsequently, to ligate the 5′ linker, 1 μL of T4 RNA ligase, 1 μL of 10× buffer, 1 μL of 10 mM ATP, 0.5 μL of 5′ linker (RA5, TruSeq Small RNA kit), and 1 μL of SUPERase-In were added to each sample and incubated for 16 hours at 22° C.
[0319] To construct cDNA libraries, the linker-ligated RNAs were reverse-transcribed in 20 μL of 1× reaction mixture containing 4 μL, of 2.5 mM dNTP, 1 μL of Superscript II RT enzyme, 4 μL, of 5× buffer, and 2 μL of 0.1 M DTT. To amplify the cDNA for Illumina DNA sequencing, 1 μL from a total of 20 of RT sample was mixed with 1 μL of Phusion HF polymerase (Thermo Fisher Scientific, F-530L), 5 μL of 5× buffer, 2.5 mM dNTP, 0.2 μL of 5′ primer (TruSeq Small RNA kit), 0.2 μL of 3′ primer (TruSeq Small RNA kit), and 33.6 μL of distilled water. This PCR mixture was run for 22-25 cycles of 98° C. for 10 seconds, 60° C. for 30 seconds, and 72° C. for 20 seconds on T1 Thermocycler. The amplified cDNA libraries were purified by Native-PAGE and from gel elute.
[0320] The purified cDNA libraries were sequenced using an Illumina HiSeq 2000 or HiSeq 2500 sequencing system. Translatome profiling led to detecting genes having mTOR mutation-mediated expression upregulation.
[0321] 8-4: Sequencing Processing and Alignment of Ribo-Seq and RNA-Seq Libraries
[0322] Some first steps in the sequence analysis were conducted using FASTX-Toolkit of Assaf Gordon (http://hannonlab.cshl.edu/fastx_toolkit/). The reads thus obtained were trimmed from the 3′ end so that the remaining reads were 26 nt long. The reads were aligned with Bowtie (http://bowtie-bio.sourceforge.net/index.shtml) version 1.1.2 to UCSC mm10 assembly to remove rRNA and tRNA Then, the reads were aligned to UCSC mm10 genome sequences using TopHat (http://ccb.jhu.edu/software/tophat/index.shtml) version 2.1.1 with default options, except for no novel junctions.
[0323] 8-5: mRNA Transcript Quantification and Normalization of Ribo-Seq and RNA-Seq Libraries
[0324] To quantify ribosome footprint and mRNA abundance of individual genes, Ribo-Seq and RNA-Seq tags were counted per individual transcript after aligning with HTSeq (https://htseq.readthedocs.io/en/release 0.9.1/). Transcripts with low read counts in the Ribo-Seq and RNA-Seq libraries (i.e., FMCD mouse model <100 raw reads in all of the libraries) were excluded to reduce noise. Each read count per individual mRNA transcript was normalized to median values of the read counts in each library.
[0325] 8-6: Quantification of Translation Efficiencies of Individual mRNA Transcripts
[0326] Translational efficiency (1 h) of mRNA transcripts for as many as 5,000 genes was calculated as the normalized read counts of an individual transcript in ribosome-protected mRNA fragments (RPFs) divided by the normalized RNA-Seq tag counts mapped to the coding sequence (CDS). The CDS-mapped RNA-Seq tag counts were also normalized to their medians in the RNA-Seq libraries. Fold changes in the translational efficiencies (TEs) of individual genes at each time point relative to the control were calculated in a log 2 scale.
[0327] 8-7: Identification of eIF4E Hyperactivation-Sensitive Gene
[0328] From the distribution of fold changes in translational efficiencies (TEs) of individual genes at each time point relative to the control, 256 genes with z-score of 1.2 or more in both MTOR-C1483Y and MTOR-L2427P models relative to MTOR-WT model were selected for eIF4E activation-sensitive genes. The z-score of 1.2 or more in the distribution of TE fold changes meets the condition of log 2(TE[p.C1483Y]/[WT])≥2.142605598 and log 2(TE[p.L2427P]/[WT])≥2.232171262. The 256 selected genes are given in Table 1.
<EXAMPLE 9> Analysis of eIF4E Hyperactivation-Sensitive Gene
[0329] 9-1: Analysis of General 5′-UTR Features
[0330] 5′-UTRs were obtained from the UCSC Genome Browser (GRCm38/mm10; https://genome.ucsc.edu/) for all genes present on the ribosome profiling. The longest 5′-UTR sequence of individual mRNAs annotated in RefSeq was selected for analysis.
[0331] mRNAs of the 256 mTOR hyperactivation-sensitive genes in FMCD mice in Table 1 were compared with all detected genes for GC content in 5′-UTR, length, and Gibbs free energy.
[0332] Minimum folding ΔG° was predicted for each sequence using QuikFold2 version 3.0 (http://mfold.ma.albany.edu/?q=DINAMelt/Quickfold) set with default parameters of RNA folding energy rules (Lee J H et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly Nat. Genet. 2012; 44(8):941-945).
[0333] 9-2: Common Motif in eIF4E Hyperactivation-Sensitive Genes
[0334] Multiple Em for motif elicitation (MEME, http://meme-suite.org/tools/meme) was performed using the MEME browser application program (version 4.12.0) (Bailey T L, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc. Second Int. Conf. Intell. Syst. Mol. Biol. 1994;28-36). 5′-UTRs were called from the UCSC Genome Browser (GRCm38/mm10), and RefSeq-annotated mRNAs with known 5′-UTRs were selected for further analysis. The longest 5′-UTR for each gene was compiled for input into MEME as a training set.
[0335] For eIF4E activation-sensitive genes in the FMCD models of Table 1, motif search parameters for a 12-nt sequence with any number of repeats using only a given strand was employed to identify guanine quartet (GGC).sub.4, CERT, A-rich, and U-rich motifs.
[0336] For the FMCD mice, eIF4E activation-sensitive genes in FMCD with RefSeq-annotated mRNAs containing known 5′-U IRs were evaluated for the presence of guanine quartet (GGC).sub.4, CERT, A-rich, and U-rich motifs using Find Individual Motif Occurrences (FIMO; http://meme-suite.org/tools/fimo).
[0337] The MEME analysis results indicate that the eIF4E hyperactivation-sensitive genes have 5′-UTR specific motifs in common (
[0338] As can be seen in
[0339]
[0340] 9-3: 5′-UTR Luciferase Reporter Assay
[0341] 5′-UTRs were obtained from the UCSC Genome Browser (GRCm38/mm10). 5′-UTRs with WT, transversion, and deletion sequences were synthesized for each of ADK-S, CREB1, and IRSp53.
[0342] In Table 8, underlined letters in bold on the ADK-S wild-type (WT) sequence stand for guanine quartet (GGC).sub.4; the first and third marks in underlined letters in bold on the CREB1 wild-type sequence stands for A-rich and U-rich motifs, respectively; and the underlined letters in bold on the IRSp53 wild-type sequence stand for a U-rich motif. In the Type, Deletion indicates sequences resulting from deleting each motif from WT.
TABLE-US-00011 TABLE 8 Strand type Gene/Type (SEQ ID NO) Sequence ADK-S-WT Sense GGGCCGCCCGCGCGCGGGGTGTGTAAGGACGAG (SEQ ID NO: 220) CTCTCCGACGCTGAGTGCCAGAGCTAGGGAGCAG TTGCTGTGGTACCTACTGCTACCTGGGCAGACGC TGAGCATCGGACATCAGGCGCGGGGCGCTGCGG TGCGGGACGGGTAGGTGCAGTC Antisense GACTGCACCTACCCGTCCCGCACCGCAGCGCCCC (SEQ ID NO: 221) GCGCCTGATGTCCGATGCTCAGCGTCTGCCCAGG TAGCAGTAGGTACCACAGCAACTGCTCCCTAGCT CTGGCACTCAGCGTCGGAGAGCTCGTCCTTACAC ACCCCGCGCGCGGGCGGCCC ADK-S- Sense GGGCCGCCCGCGCGCGGGGTGTGTAAGGACGAG Deletion (SEQ ID NO: 222) CTCTCCGACGCTGAGTGCCAGAGCTAGGGAGCAG TTGCTGTGGTACCTACTGCTACCTGGGCAGACGC TGAGCATCCGCTGCTGCAGTC Antisense GACTGCAGCAGCGGATGCTCAGCGTCTGCCCAGG (SEQ ID NO: 223) TAGCAGTAGGTACCACAGCAACTGCTCCCTAGCT CTGGCACTCAGCGTCGGAGAGCTCGTCCTTACAC ACCCCGCGCGCGGGCGGCCC CREB1-WT Sense TCGGCACTGGGCGGCGCTGGCTGGCTCCCTGG (SEQ ID NO: 224) CTGCGGCTCCTCAGTCGGCGGCGGCTGCTGCTG CCTGTGGCCCGGGCGGCTGGGAGAAGCGGAGTG TTGGTGAGTGACGCGGCGGAGGTGTAGTTTGACG CGGTGTGTTACGTGGGGGAGAGAATAAAACTCC AGCGAGATCCGGGCCGCGAACGAAAGCAGTGAC GGAGGAGCTTGTACCACCGGTATCC Antisense GGATACCGGTGGTACAAGCTCCTCCGTCACTGCT (SEQ ID NO: 225) TTCGTTCGCGGCCCGGATCTCGCTGGAGTTTTATT CTCTCCCCCACGTAACACACCGCGTCAAACTACA CCTCCGCCGCGTCACTCACCAACACTCCGCTTCTC CCAGCCGCCCGGGCCACAGGCAGCAGCAGCCGC CGCCGACTGAGGAGCCGCAGCCAGGGAGCCAGC CAGCGCCGCCCAGTGCCGA CREB1- Sense TCCTGGCTCCCTGGCTGCGGCTCCTCAGTCGGCG Deletion1 (SEQ ID NO: 226) GCGGCTGCTGCTGCCTGTGGCCCGTGAGTGACGC GGCGGAGGTGTAGTTTGACGCGGTGTGTTACGTG GGGGAGAGAATAAAACTCCAGCGAGATCCGGGC CGCGAACGAAAGCAGTGACGGAGGAGCTTGTAC CACCGGTATCC Antisense GGATACCGGTGGTACAAGCTCCTCCGTCACTGCT (SEQ ID NO: 227) TTCGTTCGCGGCCCGGATCTCGCTGGAGTTTTATT CTCTCCCCCACGTAACACACCGCGTCAAACTACA CCTCCGCCGCGTCACTCACGGGCCACAGGCAGCA GCAGCCGCCGCCGACTGAGGAGCCGCAGCCAGG GAGCCAGGA CREB1- Sense TCGGCACTGGGCGGCGCTGGCTGGCTCCCTGGCT Deletion2 (SEQ ID NO: 228) GCGGCTCCTCAGTCGGCGGCGGCTGCTGCTGCCT GTGGCCCGGGCGGCTGGGAGAAGCGGAGTGTTG GTGAGTGACGCGGCGGAGGTGTAGTTTGACGCGG TGTGTTACGTGGGGGCTCCAGCGAGATCCGGGCC GCGAACGAAAGCAGTGACGGAGGAGCTTGTACC ACCGGTATCC Antisense GGATACCGGTGGTACAAGCTCCTCCGTCACTGCT (SEQ ID NO: 229) TTCGTTCGCGGCCCGGATCTCGCTGGAGCCCCCA CGTAACACACCGCGTCAAACTACACCTCCGCCGC GTCACTCACCAACACTCCGCTTCTCCCAGCCGCCC GGGCCACAGGCAGCAGCAGCCGCCGCCGACTGA GGAGCCGCAGCCAGGGAGCCAGCCAGCGCCGCC CAGTGCCGA CREB1- Sense TCGGCACTGGGCGGCGCTGGCTGGCTCTCATGCT Deletion3 (SEQ ID NO: 230) GCCTGTGGCCCGGGCGGCTGGGAGAAGCGGAGT GTTGGTGAGTGACGCGGCGGAGGTGTAGTTTGAC GCGGTGTGTTACGTGGGGGAGAGAATAAAACTCC AGCGAGATCCGGGCCGCGAACGAAAGCAGTGAC GGAGGAGCTTGTACCACCGGTATCC Antisense GGATACCGGTGGTACAAGCTCCTCCGTCACTGCT (SEQ ID NO: 231) TTCGTTCGCGGCCCGGATCTCGCTGGAGTTTTATT CTCTCCCCCACGTAACACACCGCGTCAAACTACA CCTCCGCCGCGTCACTCACCAACACTCCGCTTCTC CCAGCCGCCCGGGCCACAGGCAGCATGAGAGCC AGCCAGCGCCGCCCAGTGCCGA IRSp53- Sense GTGGTCCTGGTCTGCGCGCCTTTTCCTGTTGCTG WT (SEQ ID NO: 232) CAGTTGTCGCTTTCCTCACCGCCACCCGTGCCCCT GCTCTGGTCTGTGGTGTAGCCGGGACCCAGGACC Antisense GGTCCTGGGTCCCGGCTACACCACAGACCAGAGC (SEQ ID NO: 233) AGGGGCACGGGTGGCGGTGAGGAAAGCGACAAC TGCAGCAACAGGAAAAGGCGCGCAGACCAGGAC CAC IRSp53- Sense GTGGTCCTGGTCTGCGCGCCAGTTGTCGCTTTCCT Deletion (SEQ ID NO: 234) CACCGCCACCCGTGCCCCTGCTCTGGTCTGTGGTG TAGCCGGGACCCAGGACC Antisense GGTCCTGGGTCCCGGCTACACCACAGACCAGAGC (SEQ ID NO: 235) AGGGGCACGGGTGGCGGTGAGGAAAGCGACAAC TGGCGCGCAGACCAGGACCAC
[0343] The synthesized 5′-UTR was cloned into a site between the SV40 promoter and the firefly luciferase open reading frame in the pGL3-promoter vector (Promega, E1761), using HindIII (NEB, R3104) and NcoI (NEB, R3193). Renilla pGL4.74 was used as a control reporter. HEK293T cells were co-transfected with a mixture of 30:30:1 of pGL3-SV40 5′-UTR reporter; FLAG-tagged mTOR WT, FLAG-tagged mTOR p.Cys1483Tyr, or FLAG-tagged mTOR p.Leu2427Pro; and pGL4.74 control reporter, using iNfect transfection reagent. Cells were harvested 24 hours after transfection and lysed. The cell lysate was measured for luciferase activity using a Dual Luciferase Assay kit (Promega, E1960). Firefly luciferase activity was normalized to Renilla activity and was expressed as values relative to HEK293T cells transfected with FLAG-tagged mTOR WT.
[0344]
[0345]
[0346] In
[0347] As can be understood from the data of
<EXAMPLE 10> Repeated Dose Toxicity Assay
[0348] ASO #16, #21, #27, #35, #75, #77, and #89 selected in Example 4 were each assayed for repeated dose toxicity by subcutaneous injection.
[0349] Repeated dose toxicity assay of the MO sequences was conducted by Biotoxtech Co., Ltd. In repeated dose toxicity assay, each ASO sequence was subcutaneously injected at a dose of 100 mg/kg to groups of four male mice seven times in total within a month (days 1, 3, 5, 7, 14, 21, and 28). Two days after the last injection, histopathologic observations were made.
[0350] No dead or moribund animals were observed in ASO #16, #21, #27, #35, #75, and #77 test groups whereas all animals in the ASO #89 test group were dead or in a moribund state. Except for ASO #89 test group, all the test groups were free of behavioral abnormality.
[0351] The toxicity of ASO #89 might be attributed to the sequence thereof other than the 2′-MOE gapmer chemically modified structure typically known, or might result from effect on the expression of off-target genes other than the target gene. The in-silico off-target gene analysis in Example 4-4 revealed that ASO #16, #21, #27, #35, #75, and #77, which each target eIF4E, are free of off-target genes coincident with the remaining 19 nucleotide sequences except for 1 nucleotide sequence whereas there are four off-target genes for ASO #89.